| Excerpt | Reference |
|---|
| "In the U." | ( Mocsny, N, 1992) |
| "Cryptococcal meningitis is a common cause of chronic meningitis in Papua New Guinea, affecting apparently immunocompetent people." | ( Fisher, D; Lalloo, D; Laurenson, I; Mavo, B; Naraqi, S; Saweri, A; Sinha, A; Temu, P, 1994) |
| "The problem of cryptococcal meningitis is likely to become increasingly common as HIV infection becomes more widespread." | ( Maher, D; Mwandumba, H, 1994) |
| "Cryptococcal meningitis is a common manifestation of cryptococcosis in people with AIDS." | ( Maher, D; Mwandumba, H, 1994) |
| "We conclude that cryptococcal meningitis is a rare complication in liver transplant recipients (0." | ( Fung, J; Jabbour, N; Kusne, S; Martin, M; Reyes, J, 1996) |
| "Cryptococcal meningitis is a difficult disease to treat and requires biochemical and haematological monitoring to detect the common adverse effects of treatment." | ( Seaton, RA, 1996) |
| "Cryptococcal meningitis is one of the major complications affecting the central nervous system of patients suffering from AIDS." | ( Anunnatsiri, S; Chetchotisakd, P; Choksawadphinyo, K; Mootsikapun, P, 2003) |
| "Cryptococcal meningitis is an uncommon but often fatal complication of systemic lupus erythematosus (SLE)." | ( Chi, C; Chiu, C; Fu, L; Liou, J; Tseng, C, 2003) |
| "Cryptococcal meningitis is the third-most-common opportunistic infection in HIV patients in Cambodia." | ( Buisson, Y; Keo, C; Monchy, D; Sar, B; Sarthou, JL; Vann, M, 2004) |
| "Cryptococcal meningitis is a common opportunistic infection in AIDS patients, particularly in Southeast Asia and Africa." | ( Bicanic, T; Harrison, TS, 2004) |
| "Cryptococcal meningitis is a leading cause of HIV-related mortality in Africa, but current guidelines do not advocate CRAG testing as a screening tool." | ( Coutinho, A; Downing, R; Ekwaru, JP; Liechty, CA; Mermin, J; Ransom, RL; Solberg, P; Weidle, PJ; Were, W, 2007) |
| "Cryptococcal meningitis is the most common life-threatening fungal infection and is associated with high mortality in children." | ( Gao, F; Jiang, PF; Shen, SX; Shui, QX; Xia, ZZ; Yu, HM; Zhou, BL, 2010) |
| "Cryptococcal meningitis is a major cause of human immunodeficiency virus (HIV)-associated morbidity and mortality in Africa." | ( Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010) |
| "Cryptococcal meningitis is a disease with high mortality and refractory to intravenous antifungal treatments with agents such as amphotericin B and fluconazole." | ( Hai, W; Jianghan, C; Julin, G; Yuchong, C, 2011) |
| "Cryptococcal meningitis is the commonest cause of adult meningitis in Southern Africa." | ( Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Williams, Z, 2010) |
| "Cryptococcal meningitis is an uncommon but well-known and frequently fatal complication of systemic lupus erythematosus (SLE)." | ( Tristano, AG, 2010) |
| "Cryptococcal Meningitis is common among patients with immune-suppression." | ( Alemu, S; Asefa, A; Assefa, A; Diro, E; Seboxa, T, 2010) |
| "Cryptococcal meningitis is considered rare in immunocompetent patients and is mainly a disease of immunocompromised patients." | ( Banerjee, G; Gupta, P; Khare, V; Malik, S; Mehrotra, A; Mehrotra, S; Singh, M, 2011) |
| "Cryptococcal meningitis is much less common in children than adults." | ( Diagne, NR; Diop, AG; Ndiaye, M; Ndiaye, MM; Seck, LB; Sène, MS; Sow, AD; Sow, HD, 2011) |
| "Cryptococcal meningitis is mainly caused by Cryptococcus neoformans and Cryptococcus gattii, but occasionally other Cryptococcus species and phylogenetically related species are involved." | ( Boekhout, T; Hagen, F; Liao, W; Meis, JF; Pan, W; Shi, W; Theelen, B, 2012) |
| "Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to administer." | ( Allain, T; Chikafa, J; Denis, B; Feasey, NA; Goodson, P; Harrison, T; Heyderman, RS; Lalloo, DG; Mukaka, M; Rothe, C; Sloan, DJ; van Oosterhout, JJ, 2013) |
| "Cryptococcal meningitis is a relatively common invasive fungal infection in immunocompromised patients, especially in solid organ transplant recipients." | ( Alangaden, G; Carron, M; Chandrasekar, P; Iyer, SP; Movva, K; Revankar, SG; Tranchida, P; Wiebel, M, 2013) |
| "Cryptococcal meningitis is a significant and neglected infection that is associated with excessive morbidity and mortality." | ( Felton, T; Goodwin, J; Gregson, L; Harrison, TS; Hope, WW; Howard, SJ; Livermore, J; Moser, B; Müller, W; Perfect, JR; Schwartz, JA; Sharp, AD; Walker, C, 2014) |
| "Cryptococcal meningitis is a rare disease in Europe, resulting in delayed recognition and slower initiation of specific treatment." | ( Arastéh, K; Katchanov, J; Stocker, H; von Kleist, M, 2014) |
| "Cryptococcal meningitis is associated with significant morbidity and is rare among immunocompetent patients." | ( Almeida, AC; Costa, JM; Passarinho, MP; Portelinha, J, 2014) |
| "Cryptococcal meningitis is a mycosis encountered especially in patients with Acquired Immunodeficiency Syndrome and is fatal in the absence of treatment." | ( Bertout, S; Boyom, FF; Delaporte, E; Dongtsa, J; Fomena, S; Kammalac Ngouana, T; Kouanfack, C; Mallié, M; Tonfack, C, 2015) |
| "Symptoms of cryptococcal meningitis are non-specific: headache, fever, nausea, or altered mental state and behaviour." | ( Aliredjo, RP; de Jong, PY; de Sévaux, RG; Nooijen, S; van Spil, WE; Verhave, JC, 2015) |
| "Cryptococcal meningitis is uncommon in children, particularly in infants." | ( O'Reilly, DA, 2016) |
| "Cryptococcal meningitis is the most common fungal infection of the central nervous system (CNS) in HIV/AIDS." | ( Cao, H; Chi, F; Huang, SH; Jong, A; Liu, LQ; Peng, L; Wang, SF; Wu, CH; Yu, JY; Zhang, B, 2015) |
| "Cryptococcal meningitis is a critical illness affecting 0." | ( Bedouch, P; Brion, JP; Camara, B; Claustre, J; Pison, C; Quétant, S, 2018) |
| "Cryptococcal meningitis is a severe opportunistic infection in HIV-infected patients." | ( Bellet, V; Bertout, S; Delaporte, E; Doumbia, A; Drakulovski, P; Gatchitch, F; Kassi, FK; Kouakou, GA; Krasteva, D; Mallié, M; Menan, HIE; Reynes, J, 2016) |
| "Cryptococcal meningitis is an important fungal infection among systemic lupus erythematosus patients." | ( Boekhout, T; Chen, M; Deng, D; Fang, W; Guo, Y; Hagen, F; Liao, W; Liu, J; Ms, A; Pan, W; Xu, J; Zhang, P, 2016) |
| "Cryptococcal meningitis is one of the leading causes of death in HIV/AIDS patients." | ( Alastruey-Izquierdo, A; Aller, AI; Cuesta, I; Gago, S; Gómez-López, A; Martín-Mazuelos, E; Mellado, E; Serrano, C, 2017) |
| "Cryptococcal meningitis is the second most common cause of the opportunistic neuroinfections." | ( Beno, P; Kaiglova, A; Samohyl, M, 2017) |
| "Cryptococcal meningitis is a potentially fatal fungal infection associated with a significant attributable morbidity and mortality, especially among HIV/AIDS patients." | ( Camacho-Ortiz, A; Castillo-Reyna, L; Galindo-Alvarado, SG; González, GM; Hernández-Rodríguez, PA; Martínez-Reséndez, MF; Treviño-Rangel, RJ; Villanueva-Lozano, H, 2018) |
| "Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide." | ( Eshun-Wilson, I; Ford, N; Jarvis, JN; Li, T; Rouse, B; Shapiro, AE; Tenforde, MW, 2018) |
| "Cryptococcal meningitis is responsible for around 15% of all HIV-related deaths globally." | ( Alufandika, M; Bango, F; Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Dziwani, E; Gondwe, E; Harrison, TS; Hlupeni, A; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Kanyama, C; Lalloo, DG; Lawrence, DS; Lortholary, O; Loyse, A; Maheswaran, H; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Muthoga, C; Muzoora, CK; Mwandumba, H; Ndhlovu, CE; Niessen, LW; Ponatshego, PL; Rajasingham, R; Sayed, S; Shamu, S; Shiri, T; Tsholo, K; Tugume, L; Wang, D; Williams, D; Youssouf, N, 2019) |
| "Cryptococcal meningitis is an opportunistic infection predominantly affecting immunocompromised patients but rarely can affect the immunocompetent." | ( Khattab, A; Patruni, S; Sealey, ML, 2019) |
| "Cryptococcal meningitis is a severe subacute fungal meningoencephalitis." | ( Li, X; Wan, Y; Wang, Y; Yang, S; Yu, Y, 2020) |
| "Cryptococcal meningitis is a fungal infection that is most commonly thought of as an opportunistic infection affecting immunocompromised patients, classically patients with Human Immunodeficiency (HIV) infection." | ( Lacy, AJ; Murphy, LS; Shah, KS; Smith, AT, 2020) |
| "Cryptococcal meningitis is an important cause of morbidity and mortality in HIV infected individuals." | ( Bhati, R; Bohra, GK; Kumar, D; Meena, DS; Midha, NK; Pramendra, S; Sejoo, B; Verma, D, 2021) |
| "Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa." | ( Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Harrison, TS; Hlupeni, A; Hope, W; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kagimu, E; Kanyama, C; Kasibante, J; Lalloo, DG; Lawrence, DS; Leeme, T; Lortholary, O; Loyse, A; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Mpoza, E; Mutata, C; Muzoora, C; Mwandumba, HC; Mzinganjira, H; Ndhlovu, CE; Nuwagira, E; Rhein, J; Rutakingirwa, MK; Schutz, C; Siamisang, K; Singh, A; Ssebambulidde, K; Tugume, L; van Widenfelt, E; Wang, D; Youssouf, N, 2022) |
| "Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the Cryptococcus genus." | ( Day, JN; Flower, B; Ngan, NTT, 2022) |
| "HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality." | ( Bango, F; Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Dziwani, EN; Harrison, TS; Hlupeni, A; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kanyama, C; Lawrence, DS; Leeme, T; Maheswaran, H; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Muthoga, C; Muzoora, C; Mwandumba, HC; Ndhlovu, CE; Niessen, LW; Nuwagira, E; Rajasingham, R; Schutz, C; Shamu, S; Shiri, T; Tugume, L; Williams, D; Youssouf, N, 2022) |
| "HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality." | ( Bango, F; Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Dziwani, EN; Harrison, TS; Hlupeni, A; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kanyama, C; Lawrence, DS; Leeme, T; Maheswaran, H; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Muthoga, C; Muzoora, C; Mwandumba, HC; Ndhlovu, CE; Niessen, LW; Nuwagira, E; Rajasingham, R; Schutz, C; Shamu, S; Shiri, T; Tugume, L; Williams, D; Youssouf, N, 2022) |
| "HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality." | ( Bango, F; Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Dziwani, EN; Harrison, TS; Hlupeni, A; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kanyama, C; Lawrence, DS; Leeme, T; Maheswaran, H; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Muthoga, C; Muzoora, C; Mwandumba, HC; Ndhlovu, CE; Niessen, LW; Nuwagira, E; Rajasingham, R; Schutz, C; Shamu, S; Shiri, T; Tugume, L; Williams, D; Youssouf, N, 2022) |
| Excerpt | Reference |
|---|
| "A 25-year-old pregnant women with cryptococcal meningitis treated with itraconazole during the first few weeks and 12th-16th week of pregnancy is reported." | ( Chotmongkol, V; Sookprasert, A, 1992) |
| "After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse." | ( Cloud, GA; Follansbee, SE; Graybill, JR; Jacobson, JM; McAuliffe, VJ; Meyer, RD; Powderly, WG; Robinson, P; Saag, MS; Sugar, AM, 1992) |
| "Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus flucytosine is associated with a failure rate of 20%-30%." | ( Powderly, WG, 1992) |
| "Two of three patients with acute cryptococcal meningitis completed the 12-week primary therapy, and one patient was discontinued from therapy because of a skin rash (95% confidence interval, 14-100%)." | ( Chambers, HF; Lee, BL; Padula, AM; Sande, MA; Täuber, MG, 1992) |
| "Three patients with AIDS who had cryptococcal meningitis were treated with liposomal amphotericin B after unsuccessful treatment with fluconazole and conventional amphotericin B." | ( Coker, RJ; Harris, JR; Murphy, SM, 1991) |
| "Treatment of cryptococcal meningitis with amphotericin B or fluconazole is often unsuccessful; in only 35%-40% of cases do CSF cultures become negative by 10 weeks after initiation of such therapy." | ( Bauer, M; Bozzette, SA; Forthal, D; Haghighat, D; Jones, BE; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Tilles, JG, 1994) |
| "Four patients with cryptococcal meningitis have been treated with fluconazole in the past two years at the Department of Neurology, National Cheng Kung University Medical Center." | ( La, ML; Ong, CT; Tsai, JJ, 1993) |
| "Treatment of cryptococcal meningitis was successful in 17 of the 19 patients given fluconazole but only three of the six receiving itraconazole." | ( Cartledge, J; Fisher, M; Gazzard, BG; Nelson, MR; Rogers, T, 1994) |
| "We report a case of cryptococcal meningitis in a 31-year-old HIV-positive man which was successfully treated with amphotericin B lipid emulsion." | ( Appleyard, MN; Hartley, JP; Leake, HA, 1994) |
| "After he was diagnosed as cryptococcal meningitis using the microscopy, cryptococcal antigen detection and culture of cerebrospinal fluid, treatment with amphotericin-B and fluconazole was started." | ( Imae, N; Konishi, M; Maeda, K; Masutani, T; Migita, T; Mikasa, K; Mori, K; Narita, N; Sano, R; Sawaki, M; Yamanaka, T; Yoshioka, A, 1996) |
| "To describe a patient with cryptococcal meningitis treated with the combination of amphotericin B and fluconazole." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "A 41-year-old woman with cryptococcal meningitis who was not infected with HIV was treated with a combination of amphotericin B and fluconazole because she did not respond to amphotericin B alone and could not tolerate amphotericin B with flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "Standard therapy for cryptococcal meningitis is amphotericin B with or without flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "A patient with cryptococcal meningitis was treated with the combination of amphotericin B and fluconazole because of a poor response to amphotericin B monotherapy and intolerance to flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "HIV-infected patients with cryptococcal meningitis were randomized to treatment with either liposomal amphotericin B (AmBisome) 4 mg/kg daily or standard amphotericin B 0." | ( Allworth, T; Borleffs, JC; Clezy, K; de Marie, S; Hop, WC; Hoy, J; Jones, P; Kauffmann, RH; Kroon, FP; Leenders, AC; Portegies, P; Reiss, P; Verbrugh, HA, 1997) |
| "Four patients with cryptococcal meningitis were successfully treated with liposomal amphotericin B prepared at our institute using Soya phosphatidylcholine and cholesterol." | ( Bodhe, PV; Gokhale, PC; Kirodian, BG; Kotwani, RN; Kshirsagar, NA, 2001) |
| "4 months later he was admitted with cryptococcal meningitis and was treated successfully with amphotericin B." | ( Elias, M; Flatau, E; Raz, R; Reichman, N, 1999) |
| "Nine cases of cryptococcal meningitis or menigoencephalitis treated with Ambisome were clinically cured with an effective rate of 100%, within a mean course of 50 days, which was shorter than that of C-Amb, by a mean cumulative dose of 1807." | ( Hai, W; Wanqing, L; Wei, H, 2003) |
| "HIV infected patients with primary cryptococcal meningitis, who had been treated initially with amphotericin B for 2 weeks were included in this study." | ( Anunnatsiri, S; Chetchotisakd, P; Choksawadphinyo, K; Mootsikapun, P, 2003) |
| "Forty Thai patients with AIDS and cryptococcal meningitis, of whom 20 had been receiving oral rifampicin for at least 2 weeks to treat tuberculosis." | ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "Patients were treated for cryptococcal meningitis with amphotericin 0." | ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "Despite evidence of unresolved cryptococcal meningitis, each patient underwent implantation of a VP shunt without complication and was discharged on lifetime fluconazole therapy." | ( McGirt, MJ; Rigamonti, D; Williams, MA; Woodworth, GF, 2005) |
| "We report two patients with cryptococcal meningitis and combined immunodeficiency with unusual magnetic resonance imaging findings of gadolinium-enhancing white matter lesions, quite different from cryptococcomas and seen prior to anti-fungal treatment." | ( Kempster, P; Thyagarajan, D; Wilcox, RA, 2007) |
| "In 2000, cryptococcal meningitis was a common HIV related opportunistic infection in central Thailand requiring inpatient management but few patients suffering from it could afford a full course of treatment once infection had occurred." | ( Inverarity, D; Wright, P, 2007) |
| "Patients with cryptococcal meningitis clearly benefit from early fungicidal therapy but require long-term suppression." | ( Graybill, JR; Lewis, JS, 2008) |
| "An all oral treatment for cryptococcal meningitis is attractive, particularly where amphotericin B use is impractical." | ( Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008) |
| "Two HIV-infected patients had recurrent cryptococcal meningitis (CM) despite treatment with fluconazole and immune reconstitution with combination antiretroviral therapy (CART)." | ( Corbett, EL; Ferrand, RA; Mangeya, N; Miller, RF; Seddon, J, 2009) |
| "Considering cryptococcal meningitis in that context, this review addresses excess morbidity and mortality in developing countries, treatment in areas of limited drug availability and challenges posed by combined anticryptococcal and HIV therapy." | ( Dedicoat, MJ; Lalloo, DG; Sloan, DJ, 2009) |
| "Progress in therapy for cryptococcal meningitis has been slow because of the lack of a suitable marker of treatment response." | ( Bekker, LG; Bicanic, T; Brouwer, AE; Chierakul, W; Harrison, TS; Jaffar, S; Jarvis, J; Limmathurotsakul, D; Longley, N; Loyse, A; Meintjes, G; Muzoora, C; Rebe, K; Stepniewska, K; Taseera, K; White, NJ; Wood, R, 2009) |
| "Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS." | ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, PC; Kendrick, AS; Kopetskie, H; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K, 2009) |
| "We provided pharmaceutical care for a cryptococcal meningitis case to study the role that clinical pharmacists played in clinical pharmacotherapy." | ( Li, CX; Liu, F; Zhai, SD; Zhang, XY, 2009) |
| "We present a case of relapsing cryptococcal meningitis unresponsive to standard therapy." | ( Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR, 2010) |
| "We report two children who had cryptococcal meningitis and associated increased intracranial pressure, and were treated with an Ommaya reservoir." | ( Gao, F; Jiang, PF; Shen, SX; Shui, QX; Xia, ZZ; Yu, HM; Zhou, BL, 2010) |
| "In non-AIDS patients with cryptococcal meningitis admitted to Huashan Hospital, Fudan University in Shanghai from January 1998 to December 2007, 31 were initially treated with low-dose amphotericin B and flucytosine for more than 1 week." | ( Huang, YX; Jiang, WM; Jin, JL; Ou, XT; Weng, XH; Wu, JQ; Xie, Y; Xu, B; Zhu, LP, 2010) |
| "A patient with cryptococcal meningitis and SLE, who responded well to amphotericin deoxycholate therapy, is reported." | ( Tristano, AG, 2010) |
| "Mortality related to cryptococcal meningitis remains high, and novel treatment strategies are needed." | ( Bekker, LG; Bicanic, T; Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Schutz, C; Williams, A; Williams, GN; Wood, R, 2012) |
| "We present 2 cases of HIV-related cryptococcal meningitis, persisting after 3 and 9 months, respectively, of standard treatment." | ( Gamaletsou, MN; Kontos, AN; Kontoyiannis, DP; Kordossis, T; Sipsas, NV; Stefanou, I; Tsiakalos, A, 2012) |
| "Of 46 patients with cryptococcal meningitis identified, 21 were cured after 10 weeks of treatment." | ( Chang, TY; Chen, FJ; Chien, CC; Lee, CH; Liu, JW; Lu, CH; Tang, YF, 2012) |
| "The patient with cryptococcal meningitis was treated with amphotericin B and fluconazole and the patient with cerebral aspergilloma with voriconazole." | ( Baršić, B; Mlinarić Missoni, E, 2012) |
| "Mortality and treatment failure from cryptococcal meningitis following initiation of treatment with 800 mg oral fluconazole is unacceptably high." | ( Allain, T; Chikafa, J; Denis, B; Feasey, NA; Goodson, P; Harrison, T; Heyderman, RS; Lalloo, DG; Mukaka, M; Rothe, C; Sloan, DJ; van Oosterhout, JJ, 2013) |
| "We present a case of cryptococcal meningitis in a renal transplant recipient presenting as acute sinusitis with successful treatment using fluconazole as primary therapy." | ( Alangaden, G; Carron, M; Chandrasekar, P; Iyer, SP; Movva, K; Revankar, SG; Tranchida, P; Wiebel, M, 2013) |
| "For the first time, we report a case of cryptococcal meningitis during the treatment of chronic HCV with PEG-interferon-α and ribavirin." | ( Choi, YW; Huh, KC; Kang, YW; Kim, SM; Kim, YS; Lee, KO; Lee, TH, 2014) |
| "She was diagnosed with cryptococcal meningitis and treated with antifungal therapy." | ( Almeida, AC; Costa, JM; Passarinho, MP; Portelinha, J, 2014) |
| "For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent." | ( Abassi, M; Boulware, DR; Lofgren, S; Rhein, J, 2017) |
| "Eighteen out of 26 cryptococcal meningitis patients were treated with amphotericin B (AmB)-based therapy, 16 of them with AmB deoxycholate (d-AmB) and 2 patients with liposomal AmB." | ( Cao, YH; Chen, YQ; Wang, RY; Wang, X; Wu, JQ; Zhao, HZ; Zhu, LP, 2017) |
| "Under-diagnosed cryptococcal meningitis following VP shunt insertion for treating the hydrocephalus can render a complicated VP shunt infection including infected VP shunt pseudocyst." | ( Chongtrakool, P; Dhitinanmuang, W; Jitmuang, A, 2018) |
| "Annual global deaths from cryptococcal meningitis (CM) are estimated at 180 000 and mortality is as high as 30%, even with optimal therapy." | ( Garvey, EP; Schotzinger, RJ; Sharp, AD; Warn, PA; Yates, CM, 2018) |
| "Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole monotherapy; and the fourth trial did not specify the antifungal used." | ( Bicanic, T; Eshun-Wilson, I; Okwen, MP; Richardson, M, 2018) |
| "A diagnosis of cryptococcal meningitis was made and the patient was started on 1200 mg fluconazole once daily and flucytosine 25 mg/kg four times daily as part of the Advancing Cryptococcal Treatment for Africa (ACTA) clinical trial." | ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "We present the first case of cryptococcal meningitis in a patient who was being administered everolimus for breast cancer." | ( Nakamura, T; Sato, H; Seki, S; Takase, K; Yamamoto, T; Yoshida, T, 2018) |
| "She was diagnosed with cryptococcal meningitis in diabetes and had a remarkable response to fluconazole monotherapy." | ( Chege, P; Owuor, OH, 2019) |
| "Clinical treatment of cryptococcal meningitis (CM) remains a significant challenge because of the lack of effective and safe drug therapies." | ( Han, G; Ji, C; Jiang, Y; Li, Z; Liu, N; Sheng, C; Tu, J; Wang, Y, 2019) |
| "The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made." | ( Alanio, A; Boyer-Chammard, T; Harrison, TS; Jarvis, JN; Lortholary, O; Temfack, E, 2019) |
| "Management of co-infections including cryptococcal meningitis, tuberculosis and other opportunistic infections in persons living with HIV can lead to complex polypharmacotherapy and increased susceptibility to drug-drug interactions (DDIs)." | ( Boulware, DR; Eneh, PC; Hullsiek, KH; Kiiza, D; Meya, DB; Nicol, MR; Rhein, J, 2020) |
| "Treatment of life-threatening cryptococcal meningitis (CM) is highly challenging due to the limited efficacy of the available antifungal drugs." | ( Ji, C; Li, J; Li, W; Liu, N; Sheng, C; Tu, J; Yang, W; Yun, Z, 2022) |
| "Albeit fingolimod associated cryptococcal meningitis is a rare event, Fingolimod therapy in patients with MS should be performed cautiously." | ( Darazam, IA; Gharehbagh, FJ; Hatami, F; Lotfollahi, L; Moradi, O; Nourinia, R; Rabiei, MM; Roozbeh, M; Shojaei, M, 2022) |